ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2701

Spleen Tyrosine Kinase (Syk) Regulates Systemic Lupus Erythematosus T Cell Signaling

Alexandros P. Grammatikos1, Debjani Ghosh2 and Vasileios C. Kyttaris1, 1Medicine/Rheumatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 2Department of Microbiology and Immunology, The Brody School of Medicine, East Carolina University, Greenville, NC

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: SLE, T cells and syk

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Lupus Erythematosus - Human Etiology and Pathogenesis II

Session Type: Abstract Submissions (ACR)

Background/Purpose: Systemic Lupus Erythematosus (SLE) T cells display an aberrant response to CD3/ TCR stimulation. The CD3/TCR complex in SLE is characterized by the substitution of the CD3 associated kinase Zap70 by Syk. The objective of this study is to better understand the role of Syk in the dysregulated SLE T cell phenotype.

Methods: A two-step approach was followed: (i) to examine whether increased Syk expression creates an SLE-like phenotype Syk was overexpressed in healthy blood-donor T cells; and (ii) to examine whether aberrant gene expression changes in SLE T cells can be corrected by Syk downregulation, SYK was silenced using a SYK-specific siRNA. Cells were lysed following 72h of incubation and expression levels of 36 genes previously associated with SLE measured in real-time PCR. Protein was also collected and expression changes confirmed in flow cytometry and western blot. Expression was normalized towards CD3E and GPADH for PCR and β-actin for western blot.

Results: Forced expression of Syk in normal T cells reproduced many of the aberrant gene expression changes seen in SLE. Expression of cytokine IL-21, cell surface molecule CD44, and intracellular molecules PP2A and OAS2 were found to increase in cells overexpressing SYK (fold increase over control transfected ±SEM: IL-21, 5.7±1.5; CD44, 4.2±2.2; PP2A, 1.5±1; OAS2, 1.5±0.3). Silencing of Syk in SLE T cells normalized the expression of the above molecules (fold decrease over control transfected ±SEM: IL-21, -1.9±0.2; CD44, -2.8±0.4; PP2A, -2.7±1.9; OAS2, -1.1±0.8).

Findings were confirmed at the protein level using flow cytometry (mean positive cells ±SEM: (i) empty vector vs. SYK overexpressing, IL-21, 7.9±1 vs. 13±2.3, p=0.05; CD44v6, 10.7±1.2 vs. 16±2.1, p=0.05; (ii) control vs. SYK siRNA transfected, IL-21, 18.6±2.4 vs. 11.4±1.6, p=0.03; CD44v6, 11.7±0.7 vs.7.6±1.2, p=0.05) and western blot (mean relative expression ±SEM: (i) empty vector vs. SYK overexpressing, OAS2, 0.91±0.1 vs. 1.39±0.2, p=0.05; PP2A, 0.49±0.1 vs. 1.23±0.3, p=0.05; (ii) control vs. SYK siRNA transfected, OAS2, 1.39±0.3 vs. 1.06±0.2; PP2A, 1.14±0.3 vs. 0.69±0.1).

Conclusion: Our data show that overexpression of Syk in healthy T cells recapitulates at least part of the SLE T cell phenotype. Syk overexpressing T cells may provide more help to B cells through IL21 secretion, have enhanced migration to tissues through CD44 upregulation and produce pro-inflammatory rather than counter-inflammatory cytokines. Inhibiting Syk in SLE T cells leads to the opposite effect, further underscoring Syk’s potential as a therapeutic target in SLE.


Disclosure:

A. P. Grammatikos,
None;

D. Ghosh,
None;

V. C. Kyttaris,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/spleen-tyrosine-kinase-syk-regulates-systemic-lupus-erythematosus-t-cell-signaling/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology